Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Resveratrol
The First People's Hospital of Lianyungang
Pancreatitis, Acute
1 trial -
Rifaximin
The First People's Hospital of Lianyungang
IBS - Irritable Bowel Syndrome
1 trial -
Rituximab
The First People's Hospital of Lianyungang
Hemophagocytic Lymphohistiocytosis
1 trial -
Ropivacaine
The First People's Hospital of Lianyungang
End Stage Renal Disease (ESRD)
1 trial -
Ropivacaine
The First People's Hospital of Lianyungang
Radius Fractures
1 trial -
Rosuvastatin
The First People's Hospital of Lianyungang
Hyperlipidemia
1 trial -
Rucacuzumab plus standard therapy
The First People's Hospital of Lianyungang
Acute Ischemic Stroke AIS
1 trial -
Ruxolitinib
The First People's Hospital of Lianyungang
Safety and Efficacy
2 trials -
S-1
The First People's Hospital of Lianyungang
Pancreatic Cancer
1 trial -
S-ketamine & Ropivacaine
The First People's Hospital of Lianyungang
Postoperative Analgesia
1 trial -
SGLT2 inhibitor
The First People's Hospital of Lianyungang
Type2 Diabetes
1 trial -
Sertraline
The First People's Hospital of Lianyungang
Efficacy, Team
1 trial -
Sertraline Hydrochloride
The First People's Hospital of Lianyungang
COVID-19 Vaccine Adverse Reaction
1 trial -
Shenfu Injection
The First People's Hospital of Lianyungang
Septic Shock
2 trials -
Skin stretching device (SSD)
The First People's Hospital of Lianyungang
Trauma
1 trial -
Standard BP control
The First People's Hospital of Lianyungang
Hypertension
1 trial -
Statin
The First People's Hospital of Lianyungang
Acute Coronary Syndrome
1 trial -
Sufentanil
The First People's Hospital of Lianyungang
Arteriovenous Malformation
1 trial -
Tamsulosin Oral Capsule
The First People's Hospital of Lianyungang
Ischaemic Heart Disease (IHD)
1 trial -
Tenofovir Alafenamide 25 MG
The First People's Hospital of Lianyungang
Chronic Hepatitis C
1 trial -
Tenofovir Alafenamide Tablets
The First People's Hospital of Lianyungang
Chronic Hepatitis b
1 trial -
Thalidomide
The First People's Hospital of Lianyungang
Gastric Cancer
1 trial -
Tirzepatide
The First People's Hospital of Lianyungang
Type 2 Diabetes Mellitus
1 trial -
Tislelizumab
The First People's Hospital of Lianyungang
Advanced NSCLC
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources